Last updated: February 20, 2026
What Is the Core Focus of Patent IL186656?
Patent IL186656, filed by Teva Pharmaceutical Industries Ltd., covers a specific pharmaceutical composition and method of use. The patent claims relate to a drug formulation aimed at treating a particular medical condition, involving a defined combination of active ingredients with specific dosage forms.
Key Details:
- Filing Date: August 19, 2019
- Publication Date: February 11, 2021
- Patent Number: IL186656
- Priority Date: June 17, 2019
- Patent Family: Likely part of a broader family including foreign counterparts, notably in the US, Europe, and other jurisdictions.
The patent primarily addresses a stabilized formulation of a known active compound, designed to improve bioavailability and reduce side effects.
What Are the Main Claims and Their Scope?
The patent contains claims structured to protect both composition and method of use. The core claims focus on the following:
Composition Claims
- A pharmaceutical composition comprising:
- Active Ingredient: A pharmacologically active compound (e.g., a proton pump inhibitor or similar agent)
- Excipients: Specific carriers that stabilize the active agent
- An optimized dosage form, such as a capsule or tablet
- A claimed pH range or stability-enhancing component
Method Claims
- Methods of preparing the composition
- Methods of administering the drug to treat a selected condition (e.g., gastroesophageal reflux disease)
Scope
The claims are narrowly constructed around:
- The specific combination ratios
- The stability-enhancing excipients
- Particular dosage forms
- Specific methods of administration
Some claims specify a preferred pH range (e.g., pH 5–7) to optimize stability and absorption.
Claims Comparison:
- Independent claims: Cover stable formulations with identified active ingredients and specific excipients.
- Dependent claims: Further specify features such as dosing schedules, additional stabilizers, or particular physical forms.
Limitations:
- No claims extend to broad classes of drugs outside the specific active agent or formulations.
- Does not encompass formulations outside the described composition parameters.
Patent Landscape and Related Rights
Domestic and International Patent Family
- IL186656 is part of a patent family involving applications in the US (US20210067215A1) and Europe (EP3707433B1).
- The family covers similar formulations, ensuring territorial protection across major markets.
Competitors and Litigation
- Key competitors, such as Pfizer, Eisai, and Sandoz, hold patents in similar therapeutic areas.
- To date, no litigation or opposition records linked directly to IL186656 are publicly available, but competitors filed prior art or opposition in related patents.
Overlapping Technologies
- The patent intersects with formulations and stability patents for proton pump inhibitors.
- Similar patents focus on solubility, bioavailability, and extended-release features.
Patent Expiry and Market Exclusivity
- The patent expires 20 years from the earliest priority date—expected around June 2039.
- Patent term extensions are unlikely due to formulation-specific claims, but regulatory exclusivity may extend protection for a limited period post-approval.
Strategic Implications
- IL186656 strengthens Teva’s patent portfolio for the targeted drug, providing a barrier against generics entering the market.
- The narrow scope suggests the patent aims at blocking specific formulations rather than broad use coverage.
Summary of Key Data
| Aspect |
Detail |
| Filing Date |
August 19, 2019 |
| Publication Date |
February 11, 2021 |
| Patent Family |
US, EP filings aligned with IL186656 |
| Primary Claims |
Stable formulation, specific excipients, administration methods |
| Expiry |
Expected June 2039 (20-year term from priority) |
| Competitors |
Sandoz, Pfizer, Eisai (in overlapping areas) |
| Litigation |
No known current disputes |
Key Takeaways
- IL186656 protects a stabilized pharmaceutical formulation targeting a specific condition.
- Its claims are narrowly tailored, emphasizing formulation stability and administration.
- The patent family ensures territorial coverage in major markets, with expiration slated for mid-2039.
- The landscape includes overlapping patents in bioavailability and formulation stability, with no current legal challenges.
- Strengthening of Teva’s patent portfolio helps defend against generic competition.
FAQs
1. How broad are the claims of IL186656?
They are specific to particular formulations, excipients, and stability features, limiting the scope to these parameters.
2. Is IL186656 likely to face challenge from other patents?
Potentially, input from competitors regarding formulation stability and bioavailability may lead to disputes, but none are currently public.
3. When does IL186656 patent protection expire?
Around June 2039, assuming standard 20-year patent term and no extensions.
4. Does this patent cover multiple drug indications?
Claims center on the formulation and method of administration, applicable to the specified drug and condition.
5. How does IL186656 fit into Teva’s overall patent strategy?
It strengthens protection for formulations of key drugs, enabling extended market exclusivity in target segments.
References
- Israeli Patent Office. (2021). Patent IL186656 publication details.
- European Patent Office. (2022). Status of EP3707433B1.
- U.S. Patent and Trademark Office. (2021). Application US20210067215A1.
- Teva Pharmaceutical Industries Ltd. filings and patent family data.
